Kabra Drugs Ltd (KABRADG) — shareholding pattern, promoter holding, financials and share price
About Kabra Drugs Ltd (KABRADG)
Kabra Drugs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as KABRADG and on the BSE under scrip code 524322. Its ISIN is INE323K01017.
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals. [1]
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products.
The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India.
Listed peers in Pharmaceuticals: Vasundhara Rasayans Ltd, Biofil Chemicals & Pharmaceuticals Ltd, Bacil Pharma Ltd, Vivimed Labs Ltd, Shelter Pharma Ltd, Vista Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹21.7 a share on 10 Jul 2026, Kabra Drugs Ltd (KABRADG) was valued at a price-to-earnings ratio of 10.35x against an industry P/E of 36.41x and a price-to-book of 2.09x on a book value of ₹10.4 per share as of Mar 2025. Solomo computes return on equity of 20.16% and return on capital employed of 22.88% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 10.35x
- Industry P/E
- 36.41x
- P/B
- 2.09x
- EPS (TTM)
- ₹2.1
- Book value / share
- ₹10.4
- ROE
- 20.16%
- ROCE
- 22.88%
- ROA
- 19.7%
- Debt / equity
- 0.02x
- Dividend yield
- 0%
- EBITDA margin
- 6.24%
- 52-week range
- ₹15.5 – ₹35.52
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Kabra Drugs Ltd (KABRADG) reported revenue of ₹92.74 crore, net profit of ₹4.96 crore and earnings per share of ₹2.09. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹35.41 crore and net profit ₹1.06 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0 | 0 | 0 | 0 | 92.74 |
| Net profit (₹ cr) | -0.19 | -0.34 | -0.74 | -1.09 | 4.96 |
| EPS (₹) | -0.43 | -0.77 | -1.69 | -0.46 | 2.09 |
| Measure | 1Y |
|---|---|
| Profit growth | -47.30% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 0% of Kabra Drugs Ltd (KABRADG) (unchanged from the previous quarter). Market capitalisation was ₹51 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: KUNIAMUTHUR NANJAPPAN ANAND 2.78%, SOMISETTY MALATHI LATHA 2.22%, SOMISETTY GIRIDHAR GUPTA 2.12%, VEERAMREDDY VIJAY KUMAR REDDY 1.94%, CHANDRAPRAKASH JAMNALAL KABRA 1.69%, PRIYAM SACHDEVA 1.42%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 0% | - | - | - | 100% |
| Mar 2026 | 0% | - | - | - | 100% |
| Dec 2025 | 0% | - | - | - | 100% |
| Sep 2025 | 0% | - | - | - | 100% |
| Jun 2025 | 0% | - | - | - | 100% |
| Mar 2025 | 0% | - | - | - | 100% |
| Dec 2024 | 0% | - | - | - | 100% |
| Sep 2024 | 0% | - | - | - | 100% |